SUCCOR quality: validation of ESGO quality indicators for surgical treatment of cervical cancer.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
03 10 2022
Historique:
entrez: 30 12 2022
pubmed: 31 12 2022
medline: 4 1 2023
Statut: epublish

Résumé

To evaluate whether compliance with European Society of Gynaecological Oncology (ESGO) surgery quality indicators impacts disease-free survival in patients undergoing radical hysterectomy for cervical cancer. In this retrospective cohort study, 15 ESGO quality indicators were assessed in the SUCCOR database (patients who underwent radical hysterectomy for International Federation of Gynecology and Obstetrics (FIGO) stage 2009 IB1, FIGO 2018 IB1, and IB2 cervical cancer between January 2013 and December 2014), and the final score ranged between 0 and 16 points. Centers with more than 13 points were classified as high-quality indicator compliance centers. We constructed a weighted cohort using inverse probability weighting to adjust for the variables. We compared disease-free survival and overall survival using Cox proportional hazards regression analysis in the weighted cohort. A total of 838 patients were included in the study. The mean number of quality indicators compliance in this cohort was 13.6 (SD 1.45). A total of 479 (57.2%) patients were operated on at high compliance centers and 359 (42.8%) patients at low compliance centers. High compliance centers performed more open surgeries (58.4% vs 36.7%, p<0.01). Women who were operated on at centers with high compliance with quality indicators had a significantly lower risk of relapse (HR=0.39; 95% CI 0.25 to 0.61; p<0.001). The association was reduced, but remained significant, after further adjustment for conization, surgical approach, and use of manipulator surgery (HR=0.48; 95% CI 0.30 to 0.75; p=0.001) and adjustment for adjuvant therapy (HR=0.47; 95% CI 0.30 to 0.74; p=0.001). Risk of death from disease was significantly lower in women operated on at centers with high adherence to quality indicators (HR=0.43; 95% CI 0.19 to 0.97; p=0.041). However, the association was not significant after adjustment for conization, surgical approach, use of manipulator surgery, and adjuvant therapy. Patients with early cervical cancer who underwent radical hysterectomy in centers with high compliance with ESGO quality indicators had a lower risk of recurrence and death.

Identifiants

pubmed: 36583728
pii: ijgc-2022-003790
doi: 10.1136/ijgc-2022-003790
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1236-1243

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Felix Boria (F)

Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, Madrid, Spain.

Luis Chiva (L)

Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, Madrid, Spain lchiva@unav.es.

Enrique Chacon (E)

Department of Gynecologic Oncology, Universidad de Navarra, Pamplona, Navarra, Spain.

Vanna Zanagnolo (V)

Istituto Europeo di Oncologia, Milan, Italy.

Anna Fagotti (A)

Agostino Gemelli IRCCS, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Catholic University of the Sacred Heart, Milano, Lombardia, Italy.

Ali Kucukmetin (A)

Queen Elizabeth Hospital, Gateshead, Gateshead, UK.

Constantijne Mom (C)

Amsterdam University Medical Centres, Amsterdam, Noord-Holland, The Netherlands.

Galina Chakalova (G)

University Oncologic Hospital, Sofia, Bulgaria.

Aliyev Shamistan (A)

National Center of Oncology, Baku, Azerbaijan.

Mario Malzoni (M)

Endoscopica Malzoni, Center for Advanced Endoscopic Gynecologic Surgery, Avellino, Italy.

Fabrice Narducci (F)

Department of Gynecology, Centre Oscar Lambret, Lille, France.

Octavio Arencibia (O)

Department of Gynecology, University Maternal Hospital Canary Islands, Las Palmas, Las Palmas, Spain.

Francesco Raspagliesi (F)

Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Tayfun Toptas (T)

Department of Gynecologic Oncology, Saglik Bilimleri University Antalya Research and Training Hospital, Antalya, Turkey.

David Cibula (D)

Department of Obstetrics and Gynecology, University of Prague, Prague, Czech Republic.

Dilyara Kaidarova (D)

Department of Oncogynecology, Kazahskij naucno-issledovatel'skij institut onkologii i radiologii, Almaty, Kazakhstan.

Mehmet Mutlu Meydanli (MM)

Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Education and Research Hospital, Ankara, Turkey.

Mariana Tavares (M)

IPO-PORTO, Porto, Portugal.

Dmytro Golub (D)

Department of Surgery, LISOD - Israeli Oncological Hospital, Kyiv Region, Ukraine.

Anna Myriam Perrone (AM)

Division of Gynecologic Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico S Orsola-Malpighi, Bologna, Italy.

Robert Poka (R)

Department of Obstetrics and Gynecology, Unit of Gynecologic Oncology; Institute of Obstetrics and Gynecology; Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Petra L M Zusterzeel (PLM)

Department of Gynecological Oncology, Radboudumc, Nijmegen, Netherlands.

Igor Aluloski (I)

Department of Gynecologic Oncology, University Clinic of Gynecology and Obstetrics, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopjeskopje, Macedonia.

Frederic Goffin (F)

Department of Obstetrics and Gynecology, University of Liege, Liege, Belgium.

Dimitrios Haidopoulos (D)

Division of Gynecologic Oncology, 1st Department of Obstetrics and Gynecology, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Herman Haller (H)

Clinical Hospital Center Rijeka, Rijeka, Croatia.

Robert Jach (R)

Department of Gynecology and Oncology, Jagiellonian University, Krakow, Poland.

Iryna Yezhova (I)

Lviv Oncology Center, Lviv, Ukraine.

Margarida Bernardino (M)

Department of Gynecology, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal.

Rasiah Bharathan (R)

University Hospitals of Leicester NHS Trust, Leicester, Leicester, UK.

Minna M Maenpaa (MM)

Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland.

Vladyslav Sukhin (V)

Department of Oncology, Radiology and Radiation Medicine, V N Karazin Kharkiv National University, Harkiv, Ukraine.
Department of Oncogynecology, Grigoriev Institute for Medical Radiology NAMS of Ukraine, Harkiv, Ukraine.

Jean-Guillaume Feron (JG)

Institut Curie, Paris, Île-de-France, France.

Robert Fruscio (R)

Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
Clinic of Obstetrics and Gynecology, Hospital San Gerardo, Monza, Italy.

Kersti Kukk (K)

North Estonia Medical Centre, Tallinn, Estonia.

Jordi Ponce (J)

Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalunya, Spain.

Fuat Demirkiran (F)

Istanbul University Cerrrahpasa Medical Faculty, istanbul, Turkey.

George Vorgias (G)

Metaxa Cancer Hospital of Piraeus, Piraeus, Attika, Greece.

Natalia Povolotskaya (N)

Department of Gynaecological Oncology, Queen Alexandra Hospital, Portsmouth NHS Trust, Portsmouth, UK.

Pluvio J Coronado Martín (PJ)

Department of Obstetrics and Gynecology, Hospital Clinico San Carlos IdISSC, Complutense University, Madrid, Spain.

Tiermes Marina (T)

Department of Gynecologic Oncology, La Fe University and Polytechnic Hospital, Valencia, Spain.

Ignacio Zapardiel (I)

Department of Gynecologic Oncology, La Paz University Hospital, Madrid, Spain.

Nicolò Bizzarri (N)

UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Policlinico Agostino Gemelli IRCCS, Rome, Italy.

Mikel Gorostidi (M)

Hospital Universitario Donostia, San Sebastian, Spain.

Monica Gutierrez (M)

Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, Madrid, Spain.

Nabil Manzour (N)

Department of Gynecologic Oncology, Universidad de Navarra, Pamplona, Navarra, Spain.

Arantxa Berasaluce (A)

Department of Preventive Medicine and Public Health, Clinica Universidad de Navarra, Pamplona, Navarra, Spain.

Nerea Martin-Calvo (N)

,Department of Preventive Medicine and Public Health, Universidad de Navarra, Pamplona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH